Showing results (1631-1640 of 1,659) with videos related to

Sort By:
Pageof 166
Blood|June 11, 2026
Product-Intrinsic NF-κB-Driven Transcriptional Programs Connote Durability of CAR-T Response in Multiple MyelomaJerald D Noble, Barbara C Peixoto, Meghan A Menges, et al.
Blood Cancer Journal|October 16, 2024
Immune effector cell-associated enterocolitis following chimeric antigen receptor T-cell therapy in multiple myelomaGliceida Galarza Fortuna, Rahul Banerjee, Constanza Savid-Frontera, et al.
Nature Communications|May 12, 2021
Elp2 mutations perturb the epitranscriptome and lead to a complex neurodevelopmental phenotypeMarija Kojic, Tomasz Gawda, Monika Gaik, et al.
Blood|January 26, 2026
Oncogenic SF3B1 mutations alter the splicing of mRNA noncoding regions to induce a novel therapeutic vulnerabilityMichal Sekrecki, Agata Sekrecka, Rohan R Lattupally, et al.
Physical Review Letters|September 16, 2000
Helicity dependence of gammap --> Npi below 450 MeV and contribution to the Gerasimov-Drell-Hearn sum ruleJ Ahrens, S Altieri, J R Annand, et al.
Blood Cancer Journal|March 28, 2026
Real-world outcomes with elranatamab in multiple myeloma: a multicenter analysis from the U.S. Multiple Myeloma Immunotherapy ConsortiumAndrew J Portuguese, James A Davis, Shahzad Raza, et al.
Blood Cancer Journal|June 25, 2025
Outcomes of teclistamab in patients with relapsed/refractory multiple myeloma with prior exposure to BCMA-directed therapy: a multicenter study from the U.S. Multiple Myeloma Immunotherapy ConsortiumDanai Dima, Mariola A Vazquez-Martinez, James A Davis, et al.
Blood|August 1, 2025
Sequential Targeting in Multiple Myeloma: Talquetamab, a GPRC5D bispecific antibody, as a Bridge to BCMA CAR-T cell therapyBinod Dhakal, Othman Salim Akhtar, David Fandrei, et al.
Blood Advances|April 8, 2025
Teclistamab for Patients with Heavily Pretreated Relapsed/Refractory Multiple Myeloma and Renal ImpairmentDanai Dima, Aimaz Afrough, Utkarsh Goel, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 18, 2025
Comparison of Standard-of-Care Idecabtagene Vicleucel and Ciltacabtagene Autoleucel in Relapsed/Refractory Multiple MyelomaDoris K Hansen, Lauren C Peres, Danai Dima, et al.
Pageof 166